Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

This article was originally published here

Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed

The post Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply